Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
25 February 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) (the "**Fosun Pharma Industrial**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**") received the approval from the National Medical Products Administration ("**NMPA**") for the clinical trial of 复迈宁® (generic name: Luvometinib Tablets; the "**Drug**") in combination with Anlotinib for the treatment of patients with KRAS-mutant advanced non-small cell lung cancer (NSCLC) (the "**Additional Indication**"). Fosun Pharma Industrial intends to commence the Phase II clinical trial of the Drug in China[1] when the conditions are fulfilled.

II. Basic Information and Research Progress of the Drug

The Drug is an innovative small molecule chemical drug self-developed by the Group (i.e., the Company and its subsidiaries/units, the same applies below), which is a MEK1/2 selective inhibitor.

As at the date of this announcement (i.e., 25 February 2026), the other regulatory or clinical progress of the Drug is as follows:

[1] excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below.

1.The Drug has already been approved for marketing in China with two approved indications, including (1) the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms; (2) the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.

2. The drug registrations for two additional indications of the Drug have been accepted by the NMPA and included in the List of Priority Review, including (1) the treatment of pediatric patients aged 2 years and older with Langerhans cell histiocytosis (LCH); (2) the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.

3. The Drug is at the stage of Phase III clinical trial in China for the treatment of children with low-grade glioma. The Drug is at the stage of Phase II clinical trial in China for the treatment of extracranial arteriovenous malformations.

As of January 2026, the Group had invested approximately RMB668 million (unaudited) in total in the research and development (the "**R&D**") of the Drug at this stage.

According to the latest data from IQVIA MIDAS™[2], the sales of MEK1/2 selective inhibitor worldwide amounted to approximately US$2,068 million in 2024.

III. Risk Warning

As required by the relevant laws and regulations in China, the Additional Indication for the Drug is subject to undergo a series of clinical studies and approval by the relevant national drug review department in China before it can be launched. There are certain risks in the R&D of drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

[2] Data provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

25 February 2025

*For identification purpose only